These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1300 related articles for article (PubMed ID: 28858473)

  • 1. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
    Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
    ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
    Song Y; Tang C; Yin C
    Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
    Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
    Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
    [No Abstract]   [Full Text] [Related]  

  • 4. Photosensitive and dual-targeted chromium nanoparticle delivering small interfering RNA YTHDF1 for molecular-targeted immunotherapy in liver cancer.
    Chen S; He Y; Huang X; Shen Y; Zou Q; Yang G; Fu L; Liu Q; Luo D
    J Nanobiotechnology; 2024 Jun; 22(1):348. PubMed ID: 38898486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages.
    Ngambenjawong C; Cieslewicz M; Schellinger JG; Pun SH
    J Control Release; 2016 Feb; 224():103-111. PubMed ID: 26772876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumor Microenvironment for Prostate Cancer Therapy.
    Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
    Mol Pharm; 2023 Nov; 20(11):5921-5936. PubMed ID: 37874541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer.
    Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
    Eur J Pharm Sci; 2023 Jun; 185():106427. PubMed ID: 36948408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
    Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
    J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
    Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
    Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor microenvironment-responsive macrophage-mediated immunotherapeutic drug delivery.
    Zhang X; Yue L; Cao L; Liu K; Yang S; Liang S; Liu L; Zhao C; Wu D; Wang Z; Tian R; Rao L
    Acta Biomater; 2024 Sep; 186():369-382. PubMed ID: 39097127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface Modification of Polymeric Nanoparticles with M2pep Peptide for Drug Delivery to Tumor-Associated Macrophages.
    Pang L; Pei Y; Uzunalli G; Hyun H; Lyle LT; Yeo Y
    Pharm Res; 2019 Mar; 36(4):65. PubMed ID: 30859335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Immunotherapy: Targeting Tumor-Associated Macrophages by Gene Silencing.
    Zins K; Abraham D
    Methods Mol Biol; 2020; 2115():289-325. PubMed ID: 32006408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo siRNA Delivery to Immunosuppressive Liver Macrophages by α-Mannosyl-Functionalized Cationic Nanohydrogel Particles.
    Kaps L; Leber N; Klefenz A; Choteschovsky N; Zentel R; Nuhn L; Schuppan D
    Cells; 2020 Aug; 9(8):. PubMed ID: 32824208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target delivery selective CSF-1R inhibitor to tumor-associated macrophages via erythrocyte-cancer cell hybrid membrane camouflaged pH-responsive copolymer micelle for cancer immunotherapy.
    Wang Y; Luan Z; Zhao C; Bai C; Yang K
    Eur J Pharm Sci; 2020 Jan; 142():105136. PubMed ID: 31704343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival.
    Cieslewicz M; Tang J; Yu JL; Cao H; Zavaljevski M; Motoyama K; Lieber A; Raines EW; Pun SH
    Proc Natl Acad Sci U S A; 2013 Oct; 110(40):15919-24. PubMed ID: 24046373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice.
    Jadidi-Niaragh F; Atyabi F; Rastegari A; Kheshtchin N; Arab S; Hassannia H; Ajami M; Mirsanei Z; Habibi S; Masoumi F; Noorbakhsh F; Shokri F; Hadjati J
    J Control Release; 2017 Jan; 246():46-59. PubMed ID: 27993599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer.
    Lu CS; Shiau AL; Su BH; Hsu TS; Wang CT; Su YC; Tsai MS; Feng YH; Tseng YL; Yen YT; Wu CL; Shieh GS
    J Hematol Oncol; 2020 Jun; 13(1):62. PubMed ID: 32487125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
    Yang M; Li J; Gu P; Fan X
    Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor associated macrophage-targeted microRNA delivery with dual-responsive polypeptide nanovectors for anti-cancer therapy.
    Liu L; Yi H; He H; Pan H; Cai L; Ma Y
    Biomaterials; 2017 Jul; 134():166-179. PubMed ID: 28463694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supermolecular nanovehicles co-delivering TLR7/8-agonist and anti-CD47 siRNA for enhanced tumor immunotherapy.
    Shang T; Yu X; Gu Y; Du R; Cai Y; Li Y; Zheng G; Wang C; Zhang J; Liu J; Han S; Yang B
    Int J Biol Macromol; 2023 Nov; 251():126539. PubMed ID: 37634787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.